advertisement

---

Cvenkel B 12

Showing records 1 to 12 | Display all abstracts from Cvenkel B

100822 An Evaluation of the Physicochemical Properties of Preservative-Free 0.005% (/) Latanoprost Ophthalmic Solutions, and the Impact on In Vitro Human Conjunctival Goblet Cell Survival
Freiberg JC
Journal of clinical medicine 2022; 11:

---

100646 Adverse Effects and Safety in Glaucoma Patients: Agreement on Clinical Trial Outcomes for Reports on Eye Drops (ASGARD)-A Delphi Consensus Statement
Thein AS
American Journal of Ophthalmology 2022; 241: 190-197

---

100822 An Evaluation of the Physicochemical Properties of Preservative-Free 0.005% (/) Latanoprost Ophthalmic Solutions, and the Impact on In Vitro Human Conjunctival Goblet Cell Survival
Hedengran A
Journal of clinical medicine 2022; 11:

---

100646 Adverse Effects and Safety in Glaucoma Patients: Agreement on Clinical Trial Outcomes for Reports on Eye Drops (ASGARD)-A Delphi Consensus Statement
Hedengran A
American Journal of Ophthalmology 2022; 241: 190-197

---

100822 An Evaluation of the Physicochemical Properties of Preservative-Free 0.005% (/) Latanoprost Ophthalmic Solutions, and the Impact on In Vitro Human Conjunctival Goblet Cell Survival
Heegaard S
Journal of clinical medicine 2022; 11:

---

100646 Adverse Effects and Safety in Glaucoma Patients: Agreement on Clinical Trial Outcomes for Reports on Eye Drops (ASGARD)-A Delphi Consensus Statement
Azuara-Blanco A; Arita R
American Journal of Ophthalmology 2022; 241: 190-197

---

100822 An Evaluation of the Physicochemical Properties of Preservative-Free 0.005% (/) Latanoprost Ophthalmic Solutions, and the Impact on In Vitro Human Conjunctival Goblet Cell Survival
Petrovski G; Jacobsen J; Jacobsen J
Journal of clinical medicine 2022; 11:

---

100646 Adverse Effects and Safety in Glaucoma Patients: Agreement on Clinical Trial Outcomes for Reports on Eye Drops (ASGARD)-A Delphi Consensus Statement
Cvenkel B
American Journal of Ophthalmology 2022; 241: 190-197

---

100822 An Evaluation of the Physicochemical Properties of Preservative-Free 0.005% (/) Latanoprost Ophthalmic Solutions, and the Impact on In Vitro Human Conjunctival Goblet Cell Survival
Cvenkel B
Journal of clinical medicine 2022; 11:

---

100646 Adverse Effects and Safety in Glaucoma Patients: Agreement on Clinical Trial Outcomes for Reports on Eye Drops (ASGARD)-A Delphi Consensus Statement
Gazzard G
American Journal of Ophthalmology 2022; 241: 190-197

---

100822 An Evaluation of the Physicochemical Properties of Preservative-Free 0.005% (/) Latanoprost Ophthalmic Solutions, and the Impact on In Vitro Human Conjunctival Goblet Cell Survival
Kolko M
Journal of clinical medicine 2022; 11:

---

100646 Adverse Effects and Safety in Glaucoma Patients: Agreement on Clinical Trial Outcomes for Reports on Eye Drops (ASGARD)-A Delphi Consensus Statement
Heegaard S; de Paiva CS; Petrovski G; Prokosch-Willing V; Utheim TP; Virgili G; Kolko M
American Journal of Ophthalmology 2022; 241: 190-197

---